NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis $0.10 0.00 (-2.27%) As of 08/14/2026 02:19 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About ZyVersa Therapeutics Stock (NASDAQ:ZVSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZyVersa Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1250-Day Range$0.10▼$0.2052-Week Range$0.10▼$0.30Volume3,269 shsAverage Volume36,595 shsMarket Capitalization$785.66 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. Read More Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVSA Stock News HeadlinesZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Corporate Event Calendar | OTC:ZVSAJuly 27, 2026 | benzinga.comZyVersa Therapeutics Transitions to OTC Pink MarketJuly 17, 2026 | tipranks.comA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift in the AI market is approaching, and time is short to prepare. Kaplan points to August 31st as a key turning point for AI investing. He argues the next phase will separate winners from losers, and reveals what he's watching instead of big names like Nvidia.August 16 at 1:00 AM | TradeSmith (Ad)ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 13, 2026 | globenewswire.comZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comZyversa Therapeutics Faces Financial Challenges Amid Drug DevelopmentNovember 20, 2025 | msn.comZyVersa Therapeutics Reports Third Quarter 2025 Financial ResultsNovember 19, 2025 | globenewswire.comZyVersa Therapeutics Delays 10-Q FilingNovember 14, 2025 | tipranks.comSee More Headlines ZVSA Stock Analysis - Frequently Asked Questions How have ZVSA shares performed this year? ZyVersa Therapeutics' stock was trading at $0.1336 at the beginning of the year. Since then, ZVSA shares have decreased by 25.9% and is now trading at $0.0990. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.33. When did ZyVersa Therapeutics' stock split? ZyVersa Therapeutics's stock reverse split on the morning of Friday, April 26th 2024.The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ZyVersa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZyVersa Therapeutics investors own include Tesla (TSLA), Lucid Group (LCID), NVIDIA (NVDA), XPENG (XPEV), Akebia Therapeutics (AKBA), JPMorgan Chase & Co. (JPM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings5/12/2025Today8/16/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZVSA CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees2Year Founded2014Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-109.54% Return on Assets-43.95% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book0.03Miscellaneous Outstanding Shares7,936,000Free Float4,863,000Market Cap$785.66 thousand OptionableNot Optionable Beta0.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZVSA) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
